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and a lower incidence of biopsy proven acute rejections. Therefore, IL2-Ra can 
be recommended for routine induction immunosuppressive therapy in pediatric 
renal transplantation.
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Objectives: To evaluate the efficacy and safety of machine perfusion for human 
kidneys obtained from living or cadaveric donors for transplantation. MethOds: 
We searched for systematic reviews (SR) of clinical trials that compared machine 
perfusion and static cold storage for renal graft preservation in the Cochrane Library, 
Centre for Reviews and Dissemination, Medline (via Pubmed) and LILACS databases. 
We also searched for Health Technology Assessments (HTA) in agencies websites. 
The quality of the evidence and strength of recommendation were evaluated 
according to the GRADE system. Results: We included eight studies: five SR and 
three HTA. The SR did not show statistically significant differences in graft survival, 
patient survival and primary non-function between static cold storage and machine 
perfusion groups. Patients who received grafts stored in machine perfusion showed 
better results regard to delayed graft function in all studies. Most SR presented poor 
quality of evidence, and all lead to a weak recommendation against the technology. 
The three HTA corresponded to recommendations of two agencies, one in favor of 
the machine perfusion use and the other left the choice of the storage method in 
discretion of the institution. cOnclusiOns: Considering all the studies, as well 
as their limitations, there is a lack of evidence to support the nationwide use of 
renal machine perfusion in Brazil. Despite the absence of a substitutive technology 
(the standard gold is static cold storage) the studies did not indicate results that 
represent a gain in graft and patient survival.
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Objectives: Despite technological advances in treatment modalities for end stage 
renal disease (ESRD) the disease continues to impose significant economic and 
social burdens on patients and health care systems globally. The purpose of this 
review was to compare the effectiveness of transplantation (Tx) and peritoneal 
dialysis (PD) to the more common treatment modality, hemodialysis (HD). The 
outcome of interest was the health related quality of life (HRQOL) of ESRD patients 
in the general, physical and psychological domains. MethOds: The primary com-
puterized databases searched for scholarly articles were PubMed and Medline. 
Only research studies written in English which met the inclusion criteria were 
considered. A random effects model was used to test the hypothesis of equality 
in mean treatment outcomes. Results: A total of 21 studies with a combined 
sample size of 17,099 patients were used in the review. Patients who received 
PD did not have a better HRQOL compared to patients receiving HD. However, 
the HRQOL of Tx patients was significantly better than that of HD patients in 
the physical and psychological domains. The overall effect sizes were 0.31, 95 
% CI (0.09, 0.53) and 0.29, 95 % CI (0.09, 0.50) respectively, and were statistically 
significant. cOnclusiOns: The findings support the assertion that Tx patients 
experience significantly better HRQOL than HD patients but only in the physical 
and psychological domains. Findings on the effectiveness of PD compared to HD 
as a treatment modality were inconclusive.
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Objectives: To systematically review the literature to identify studies relating to 
the humanistic burden and the cost-effectiveness of treatments for chronic urinary 
retention (CUR) in spinal cord injured (SCI) individuals. MethOds: Searches were 
made in the following databases: MEDLINE, Medline in process, EMBASE, EconLit and 
the NHS Economic Evaluation Database. No year restrictions were placed on the date 
of publication. The eligibility criteria in both reviews were adults with CUR requiring 
catheterisation. Searches were restricted to full English language publications in 
both cases. Only full economic evaluations or studies using generic utility instru-
ments were considered for inclusion. Abstracts were reviewed against pre-specified 
inclusion criteria by two of the authors, with a third providing advice in areas of 
disagreement. Data extraction was undertaken by two authors and validated by a 
third author. Results: Following de-duplication, a total of 518 and 627 abstracts 
retrieved from the cost-effectiveness and utility searches respectively were reviewed 
for inclusion. Of these, two economic evaluations and four utility studies were 
included. One of the models used the Quality Adjusted Life Year (QALY) as a meas-
ure of benefit, with the Incremental Cost-Effectiveness Ratio ranging from £3,270 
to £51,345 per QALY gained depending on the choice of interventions assessed. 
The SF-36 instrument was used in all four included utility studies. Statistically 
significant differences were observed for almost all domains in individuals with 
CUR compared to matched non-CUR individuals and HRQoL was also observed to 
be negatively associated with the level of incontinence (categories: no incontinence, 
yes monthly, yes weekly, yes daily). cOnclusiOns: There is a paucity of informa-
tion on both the cost-effectiveness and humanistic burden of interventions for adult 
CUR individuals with an SCI but what evidence there is indicated that CUR triggers 
a reduction in health related quality of life and that certain bladder management 
options are cost-effective.
Pss38
PayeR needs In emeRgIng maRKeTs: hOw shOUld These needs Be 
InclUded In deRmaTOlOgy dRUg develOPmenT Plans?
Copley-Merriman C.1, Zelt S.2, Stone G.2, Barrows S.1, Mordin M.1, Hogue S.3
1RTI Health Solutions, Ann Arbor, MI, USA, 2Stiefel, A GSK Company, Research Triangle Park, NC, 
USA, 3RTI-Health Solutions, Research Triangle Park, NC, USA
Objectives: Health technology assessment (HTA) is a rapidly growing field, and 
countries in the Asia-Pacific and Latin America regions are in the process of devel-
oping economic assessment guidelines for pharmaceutical products. The objective 
of this evaluation was to determine how emerging market payer needs should 
be included in drug development plans. MethOds: Payer needs were evaluated 
for Brazil, China, India, Japan, and South Korea. Dermatology was chosen as the 
example therapy area, because Asia and South America are large and important 
markets for dermatology. Based on the results, a process map was developed out-
lining the steps and timeline for including country-specific needs in drug develop-
ment plans. Additionally, key survey questions were developed for country-specific 
input. Results: Brazil has a formal HTA body, CONITEC (Comissao Nacional de 
Incorporaca de Technologias), which makes appraisal decisions based on cost-
effectiveness and budget impact analysis. Similarly, South Korea has a formal pro-
cess based on cost-effectiveness or cost minimization analysis. India is primarily 
a self-pay market for dermatology but has proposed pharmacoeconomic guide-
lines (ISPOR 2013) for formal assessments. In China, health economic (HE) data are 
required in negotiations for high-price products at the provincial or city level but 
not at the central level. Japan has no formal HE data requirements. Topics for key 
country survey questions included disease prevalence, economic burden, treatment 
guidelines, drug listing procedures, HTA decisions for current therapy, and key com-
parators. cOnclusiOns: Timely inclusion of payer needs in the drug development 
process is critical for market access with emerging markets.
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Objectives: Urinary incontinence (UI) is an undertreated condition. We examined 
the likelihood of receiving UI treatment in subjects having UI alone and UI along 
with different comorbidities. MethOds: This was a retrospective cross-sectional 
study of a 10% random sample of IMS LifeLink data from 2001-2011. Subjects were 
> = 18 years of age and continuously enrolled 6 months pre and post their first 
index diagnosis. UI subjects had at least two outpatient or one outpatient and one 
inpatient claims at least 7 days apart. Co-morbidities were observed in the pre- 
and post-index periods. Five mutually exclusive comorbidity groups were then 
formed: UI alone, UI with multiple sclerosis or Parkinson’s diseases or stroke, UI 
with diabetes or cardiovascular diseases, UI with arthritis or respiratory diseases 
or inflammatory bowel disease or dementia, or UI with any other co-morbidities. 
Treatment (Pharmacotherapy or behavioral therapy for UI) was observed 15 days 
pre- and 6 months post-index UI diagnosis. Logistic regression adjusted for region, 
age and Charlson comorbidity score was used to contrast these comorbidity groups 
on the likelihood of receiving treatment for UI. Results: There were 4,374 (28.15 %) 
subjects with UI who received treatment, and 11,162 (71.85 %) with UI and did not 
receive treatment. The odds of receiving treatment was only influenced by those 
with multiple sclerosis, Parkinson’s diseases or stroke subjects for those with (aOR 
= 1.46, p< 0.001). cOnclusiOns: Current guidelines recommend treatment for UI 
in the presence of multiple sclerosis, Parkinson’s diseases or stroke and our data 
suggest that treatment resembles guideline recommendations.
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Objectives: Therapy with interleukin-2 receptor antagonists (IL-2Ra) has resulted 
in significantly decreasing numbers of acute rejection episodes in adult renal 
transplant recipients. Acute rejection remains a major threat for graft failure 
resulting in increased immunosuppression and attendant comorbidities. There are 
limited data available regarding use of IL-2Ra in pediatric kidney recipients. This 
study aims to systematically identify and summarize the effects of using IL2-Ra 
for induction therapy in pediatric renal transplantation. MethOds: Databases, 
reference lists, and abstracts of conference proceedings were searched extensively 
to identify relevant RCTs from January 1991-August 2012 in all languages using fol-
lowing terms “kidney transplantation”, “renal transplantation”, “IL-2Ra”. Twenty-
eight trials were identified of which eight (N= 893) satisfied inclusion criteria: 
including patients less than 19 years old; with comparison of IL-2Ra to placebo or 
as an addition to standard therapy or as an alternative to other antibody therapy. 
Key clinical events included were graft survival and acute rejection. Heterogeneity 
was assessed using I2 statistic. With I2< 50%, fixed effects model was used. Results 
were expressed as odds ratio (OR) with 95% confidence intervals (CI) at 6 or 12 
months post-transplantation. Results: Incidence of clinically diagnosed acute 
rejection within one year of transplantation when patients received placebo was 
35% higher than those recipients who received IL-2Ra [OR 0.74; CI (0.48, 1.20); 
p= 0.18]. The use of an IL-2Ra in addition to standard double drug therapy or triple 
drug therapy significantly reduces acute rejection in the first post-transplant year 
[OR 0.55; CI (0.33, 0.90); p< 0.05]. The odds of graft survival when patients received 
IL-2Ra was 88% higher in treatment compared with placebo/no treatment/ [OR 
1.88; CI (1.2, 3.0); p< 0.05]. cOnclusiOns: IL-2Ra offers excellent allograft survival 
